Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
3.445
+0.105 (+3.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chromadex Corp CS
< Previous
1
2
3
4
Next >
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
August 19, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
August 07, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 05, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
July 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
July 22, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
July 16, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Join Russell 2000® Index
July 01, 2024
From
ChromaDex Corporation
Via
Business Wire
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
June 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
June 13, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
June 07, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
June 04, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
May 22, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports First Quarter 2024 Financial Results
May 08, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
April 25, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
April 30, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
April 24, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
April 23, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
March 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
March 06, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
February 21, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
February 05, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
January 26, 2024
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
December 20, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
November 30, 2023
From
ChromaDex Corporation
Via
Business Wire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
November 15, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
November 09, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
November 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
November 01, 2023
From
ChromaDex Corporation
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.